GlassScriptPhysician profile
Kenneth M Carnes
NPI 1003845363
$24,469.26
in general payments reported to CMS, 2019-2025
93 companies · $7,135 in 2025
The $7,135 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $447 · 2021: $1,421 · 2022: $3,616 · 2023: $3,846 · 2024: $5,883 · 2025: $7,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,863.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,221.32 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $2,152.70 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $1,296.62 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $1,274.49 | 2019-2025 | |
| Lundbeck LLC | $1,068.80 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $1,038.53 | 2019-2025 | Uplizna, Aimovig |
| Tg Therapeutics, INC. | $852.39 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $792.76 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Pfizer INC. | $778.55 | 2023-2025 | |
| Lilly USA, LLC | $623.09 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Biogen, INC. | $587.02 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Impel Pharmaceuticals INC. | $557.57 | 2022-2023 | Trudhesa |
| Neurocrine Biosciences, INC. | $540.80 | 2021-2025 | Ingrezza, Ongentys |
| Eisai INC. | $521.59 | 2021-2025 | |
| Argenx US, INC. | $464.65 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 89 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Carnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.